18 June 2013
Keywords: zambon, sheffield, begin, trials, ipratropium, msi, medarex
Article | 05 January 2000
Medarex says that in a preclinical study of MDX-44, a monoclonalantibody product for use in certain skin disorders and inflammatory
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 January 2000
19 January 2000
17 June 2013
© 2013 thepharmaletter.com